Anterior Approach to Improve the Prognosis in HCC Patients Via Decreasing Dissemination of EpCAM+ Circulating Tumor Cells

Journal of Gastrointestinal Surgery

Volumn 21, Issue 7, 2017, Pages 1112-1120

  Hao, Shenghua ^a   Chen, Shaofei ^a   Tu, Caixue ^a   Huang, Taotao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Anterior approach; Conventional approach; EpCAM+ circulating tumor cells; Hepatocellular carcinoma

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE;

ADULT; AGED; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; TUMOR EMBOLISM;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; EPITHELIAL CELL ADHESION MOLECULE; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 85017185725     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-017-3410-5     Document Type: Article

References (28)

1. Forner A, Llover JM, Bruix J: Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.
2. Poon RT, Fan ST, Wong J. Risk factors, prevention, management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000, 232(1):10–24.
3. Ozawa K. Nonconventional approaches to advanced liver cancer. In: Liver Surgery Approached Through the Mitochondria. Tokyo: Medical Tribune; 1992:117–165.
4. Li L, Wang HQ, Wang Q, Yang J, Yang JY. Anterior vs. conventional approach hepatectomy for large liver cancer: a meta-analysis. World J Gastroenterol. 2014;20(45):17235–43.
5. Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, Miyoshi H, et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 2007;133:937–950.
6. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010;52:280–281.
7. Eifler RL, Lind J, Falkenhagen D, Weber V, Fischer MB, Zeillinger R. Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept. Cytometry Part B: Clin.Cytometry, 2011; 80: 100–111.
8. Turnbull RB, Kyle K, Watson FR, Spratt J. Cancer of the colon: the influence of the no-touch isolation technique on survival rates. Ann Surg. 1967; 166:420–425.
9. Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Duration of hepatic vascular inflow clamping and survival after liver resection for hepatocellular carcinoma. Br J Surg. 2011; 98(9):1284–1290.
10. Chan KM, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Yu MC, et al. The Preference for Anterior Approach Major Hepatectomy: Experience Over 3 Decades and a Propensity Score-Matching Analysis in Right Hepatectomy for Hepatocellular Carcinoma. Medicine (Baltimore). 2015;94(34):e1385.
11. Liu CL, Fan ST, Lo CM, Poon RT, Wong J. Anterior Approach for Major Right Hepatic Resection for Large Hepatocellular Carcinoma. Ann Surg. 2000;232(1):25–31.
12. Wu TJ, Wang F, Lin YS, Chan KM, Yu MC, Lee WC. Right hepatectomy by the anterior method with liver hanging versus conventional approach for large hepatocellular carcinomas. Br J Surg. 2010; 97: 1070–1078.
13. Liu CL, Fan ST, Cheung ST, Lo CM, Ng IO, Wong J. Anterior Approach Versus Conventional Approach Right Hepatic Resection for Large Hepatocellular Carcinoma A Prospective Randomized Controlled Study. Ann Surg. 2006;244: 194–203
14. Makino Y, Yamanoi A, Kimoto T, Nazmy El-Assal O, Kohno H, Nagasue N. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma. Am J Gastroenterology 2000;95:1294–1300.
15. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, Wong J. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001;234:63–70.
16. Li WD, Zhou X, Huang ZJ, Zhang HW, Zhang L, Shang CZ, Chen YJ. Laparoscopic surgery minimizes the release of circulating tumor cells compared to open surgery for hepatocellular carcinoma. Surg Endosc. 2014, DOI: 10.1007/s00464-014-4041-5.
17. Jin JH, Niu XJ, Zou LH, Li L, Li S, Han JL, et al. AFP mRNA level in enriched circulating tumor cells from hepatocellular carcinoma patient blood samples is a pivotal predictive marker for metastasis. Cancer Letters 378 (2016) 33–37.
18. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, et al. EpCAM positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136:1012–1024.
19. Schulze K, Gasch C, Staufer K, Nashan B, Lohse A, Pantel K, Riethdorf S, et al. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 2013;133:2165–2171.
20. Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, Shi RY, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013;57(4):1458–68.
21. Lee SY, Konstantinidis IT, Eaton AA, Gönen M, Kingham TP, D'Angelica MI, Allen PJ, et al. Predicting recurrence patterns after resection of hepatocellular cancer. HPB (Oxford). 2014;16:943–53.
22. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003;197(5):753–8.
23. Yamanaka N, Okamoto E, Fujihara S, Kato T, Fujimoto J, Oriyama T, Mitsunobu M, et al: Do the tumor cells of hepatocellular carcinoma dislodge into the portal venous stream during hepatic resection? Cancer. 1992;70(9):2263–2267.
24. Matsumata T, Kanemetsu T, Takenaka K, Sugimachi K. Lack of intrahepatic recurrence of hepatocellular carcinoma by temporary portal venous embolization with starch microspheres. Surgery 1989;105(2):188–191.
25. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007;245:909–922.
26. Pawlik TM, Delman KA, Vauthey J, Belghiti J, et al: Tumor Size Predicts Vascular Invasion and Histologic Grade: Implications for Selection of Surgical Treatment for Hepatocellular Carcinoma. Liver Transp 2005; 11:1086–109.
27. Guo W, Yang XR, Sun YF, Shen MN, Ma XL, Wu J, Zhang CY, Zhou Y, Xu Y, Hu B, Zhang X, Zhou J, Fan J. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin Cancer Res. 2014;20(18):4794–805.
28. Thomas CR Jr. Dual-Modality Liver-Directed Therapy for Primary Liver Cancer. JAMA Oncol. 2015;1(6):765–768.